# Recall Notification

## PharmPix Clinical Department

*PharmPix is committed to the health and wellness of our members. The clinical team wants to communicate the latest up-to-date drug recall.*

## Recall of One Lot of Thyroid Tablets, USP 30 mg

**U.S. Food & Drug Administration Publication Date:**

08/24/2026

**National Drug Code:**

69680-166-00

**Product Description:**

Thyroid Tablets, USP 30 mg

**Batch (Lot) Number:**

504950

**Expiration Date:**

9/30/2026

**Company:**

Vitruvias Therapeutics Inc.

**Questions:**

Call Vitruvias Therapeutics, Inc. at (256) 239-9373 Monday through Friday from 9 a.m. to 5 p.m. CT.

It is for this reason that we are notifying you that on August 24, 2026, the U.S. Food and Drug Administration (FDA) published a drug recall for the following product(s): Thyroid Tablets, USP 30 mg.

### Reason for Recall

Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent.

Consumption of superpotent Thyroid tablets can cause hyperthyroidism (overactive thyroid) including, but not limited to, weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, or heart rhythm disturbances. The patient population at greater risk from superpotent thyroid are elderly, pregnant women, and infants, especially over extended periods of time. Excess levels of thyroid hormones in the elderly have been associated with adverse outcomes, particularly to cardiac health. Overtreatment of hypothyroidism in pregnancy is associated with a higher rate of maternal and fetal complications, including premature delivery and low birth weight. Overtreatment of hypothyroidism in infants may have negative effects on growth and development. To date, Vitruvias Therapeutics has not received any reports of adverse events known to be related to this recall.

### Pharmacy Required Action

**Identify** if the product is in inventory and immediately stop using and dispensing it. The product should be returned to the place of purchase or as directed in the recall notification.

**Advise** patients that they should not discontinue using the medication without contacting their healthcare provider. Patients experiencing any problem while taking or using this product must contact their physician.

Remember you can report adverse events related to this or any other drug product at MedWatch: The FDA Safety Information and Adverse Event Reporting Program by any of the following ways:

Complete and submit the MedWatch Online Voluntary Reporting Form online.

Download FDA Form 3500 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

Additional information can be found at: MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext.219. Our pharmacists will help you.

In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

REFERENCES:

1. U.S. Food and Drug Administration. (2026). *Vitruvias Therapeutics, Inc. Issues Nationwide Recall of One Lot of Thyroid Tablets USP, 30 mg Due to Potential Product Quality Issue*. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/vitruvias-therapeutics-inc-issues-nationwide-recall-one-lot-thyroid-tablets-usp-30-mg-due-potential